Online inquiry

IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2473MR)

This product GTTS-WQ2473MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ITGA4&ITGB7 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000885.6; NM_000889.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3676; 3695
UniProt ID P13612; P26010
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2473MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4028MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI 655066
GTTS-WQ10844MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M9346A
GTTS-WQ4836MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BT-062
GTTS-WQ6177MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CP-751871
GTTS-WQ5498MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ14622MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SC0001
GTTS-WQ9044MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ6464MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW